Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-06-05

EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH

View source ↗

Summary

EMA authorised Ixchiq (live attenuated chikungunya virus vaccine) for chikungunya virus indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ixchiq

Snippet

Status: Authorised. Therapeutic area: Chikungunya virus. MAH: Valneva Austria GmbH. Decision date: 05/06/2026